Fig. 2From: Response to different furosemide doses predicts AKI progression in ICU patients with elevated plasma NGAL levelsBiomarkers and furosemide responsiveness (FR) in AKI progression. The boxplots show the differences in the AKI biomarkers and FR between patients a without and with the progression to AKI stage 3 and b without and with the progression to AKI stage 3 or death within 1 week. *p < 0.01Back to article page